Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084200 | 0.84 | MGAM (0.51) | CYP19A1CYP17A1NPC1POLBRAB9A | |
| SCHEMBL6083838 | 0.82 | ALOX15 (0.54) | ALOX15HTTPLK1DOT1LHTR3A | |
| SCHEMBL22822742 | 0.81 | HSP90AA1 (0.46) | ALOX15NPC1RAB9AHSP90AA1CKS1B | |
| SCHEMBL6085817 | 0.78 | CNR2 (0.60) | ALOX15HTTPLK1POLBHTR3A | |
| SCHEMBL8129733 | 0.76 | HSP90AA1 (0.48) | CYP19A1CYP17A1RAB9AHSP90AA1CKS1B | |
| SCHEMBL25294487 | 0.75 | HTT (0.74) | ALOX15HTTPLK1DOT1LNPC1 | |
| SCHEMBL30718649 | 0.74 | ALOX15 (1.00) | ALOX15HTTPLK1DOT1LCYP19A1 | |
| SCHEMBL25255693 | 0.74 | HTT (0.72) | ALOX15HTTPLK1DOT1LNPC1 | |
| SCHEMBL265015 | 0.74 | ALOX15 (1.00) | ALOX15HTTPLK1DOT1LCYP19A1 | |
| SCHEMBL26240670 | 0.74 | CES2 (0.44) | ALOX15NPC1RAB9AHSP90AA1CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349044-A | Aromatic amine derivative synthesized by deconstruction of azaarene, and method and application thereof | 华南理工大学 | 2020-06-30 | — | — | CN | disclosed |
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| CN-1554649-A | Metabotropic glutamate receptor antagonists for treating central nervous system diseases | NPSҩ������˾ | 2004-12-15 | — | — | CN | disclosed |
| CN-1158264-C | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPSҩ������˾ | 2004-07-21 | — | — | CN | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| CN-1285820-A | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPS PHARMA INC (US) | 2001-02-28 | — | — | CN | disclosed |
| EP-1037878-A2 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999026927-A2 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | ALOX15 2314/4885HTT 338/4885PLK1 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.